Evaluation of the mannan antigen assay in neonates with or without Candida albicans colonization

Vasiliki Bourika1, Tania Siahanidou1, Kalliopi Theodoridou2

  • 1Neonatal Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece.

Medical Mycology
|January 3, 2024
PubMed

Insights

Mannan antigen (MA) testing shows high specificity for detecting invasive candidemia in neonates. This diagnostic marker could aid in identifying serious Candida infections in high-risk infants.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Clinical Diagnostics

Background:

  • Invasive candidemia is a serious concern in neonatal intensive care units (NICUs).
  • Candida spp. infections affect 4% of NICU admissions.
  • Mannan antigen (MA) as a marker for invasive candidemia in neonates is understudied.

Purpose of the Study:

  • To evaluate the diagnostic performance of Mannan antigen (MA) testing.
  • To assess MA's utility in neonates with rectal Candida colonization versus controls.
  • To determine the specificity of the Platelia™ Candida AgPlus kit in a neonatal population.

Main Methods:

  • A case-control study involving 340 neonates.
  • Rectal swabs were cultured to identify Candida colonization.
  • Mannan antigen (MA) levels were measured using the Platelia™ Candida AgPlus kit.

Main Results:

  • MA testing demonstrated 96% specificity in neonates with *C. albicans* rectal colonization (24/25 positive).
  • MA testing showed 100% specificity in non-colonized neonates (30/30 positive).
  • The assay exhibited high specificity in the evaluated neonatal cohort.

Conclusions:

  • Mannan antigen (MA) testing presents high specificity for diagnosing invasive candidemia in neonates.
  • The Platelia™ Candida AgPlus kit shows potential as a valuable diagnostic tool.
  • This assay could assist clinicians in identifying candidemia in neonates at risk.

Related Concept Videos

Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...